奥雌酯 | 13885-31-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 奥雌酯
• 英文名称: Orestrate
• 英文别名: [(8R,9S,13S,14S,17S)-17-(cyclohexen-1-yloxy)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] propanoate
• CAS: 13885-31-9
• 化学式: C₂₇H₃₆O₃
• 分子量: 408.581
• InChiKey: VYAXJSIVAVEVHF-RYIFMDQWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  苯甲酸雌二醇 在 吡啶 、 potassium carbonate 、 对甲苯磺酸 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 奥雌酯
  参考文献：
  名称：

  1,3,5（10）-雌二醇-17-烯醇醚和乙缩醛。新型的口服和非肠道活性雌激素衍生物。

  摘要：

  DOI：

  10.1021/jm00260a009

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Methods and devices for the treatment of ocular conditions
  申请人：deJuan Eugene

  公开号：US20060110428A1

  公开（公告）日：2006-05-25

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.
• METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS
  申请人：deJuan Eugene

  公开号：US20110159073A1

  公开（公告）日：2011-06-30

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.
• Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders
  申请人：Biocopea Limited

  公开号：US20160008376A1

  公开（公告）日：2016-01-14

  The present specification discloses compositions comprising at least one therapeutic compound capable of modulating a level and/or activity of a hormone and methods and uses for treating a gender-biased immune disorder using such compositions.
• COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS
  申请人：INITIUM INNOVATIONS, INC.

  公开号：US20190298646A1

  公开（公告）日：2019-10-03

  Disclosed herein are sustained release compositions of anti-inflammatory agents and methods of use. In some embodiments, the biodegradable sustained release compositions comprise an effective amount of an anti-inflammatory agent selected from a steroid, ta calcineurin inhibitor, a PDE4 inhibitor, an antibiotic, and combinations thereof. Also disclosed herein are methods to treat an inflammatory condition in a subject by administering a biodegradable sustained release compositions of the anti-inflammatory agent.